Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

On-chip model of mucociliary clearance for the design of drug formulations aimed at chronic respiratory diseases

Descripción del proyecto

Imitar el aclaramiento de las vías respiratorias en un chip

El sistema respiratorio dispone de un mecanismo de defensa fundamental denominado «aclaramiento mucociliar» (AMC), que consiste en la acción concertada del moco y los cilios para eliminar partículas inhaladas, microorganismos patógenos y otros residuos de las vías respiratorias. Al mismo tiempo, sin embargo, limita la eficacia de las inhaloterapias en las enfermedades respiratorias. El objetivo del proyecto MuST, financiado por las acciones Marie Skłodowska-Curie, es identificar fármacos que puedan atravesar el AMC. Para lograrlo, los investigadores se proponen crear un modelo del AMC con un chip microfluídico que les permita cribar nuevas formulaciones en función de su capacidad para desplazarse a través del moco. Se prevé que esta alternativa a los modelos celulares contribuya a mejorar el tratamiento de las enfermedades respiratorias crónicas.

Objetivo

Chronic respiratory diseases (CRDs) caused 4 million deaths worldwide in 2019. CRD treatments are often administered by inhalation in particulate formulations. However, mucociliary clearance (MCC) acts as an effective physical barrier that prevents drugs from reaching the target cells. This mechanism relies on the beating of cilia on the bronchi surface, which allows the displacement of the overlying mucus layer. Inhaled drugs are thus trapped by the mucus and quickly evacuated from the airways.
The objective of the MuST project is to model the mechanism of MCC using a microfluidic chip, to assess drug penetration through the moving mucus and thus provide a screening platform for new drug formulations. Our main objective can be subdivided into three research objectives: 1) Develop an adequate synthetic mucus model; 2) Reproduce the mucociliary clearance mechanism on a microfluidic chip; 3) Screen innovative drug formulations using our chip.
In this project, we combine expertise in biophysics, physical chemistry, soft condensed matter, and nanomedicine. The originality of our approach lies in 3 key aspects: 1) We will develop a synthetic mucus model that reproduces all the properties of native human mucus; 2) We choose to design a non-cellular MCC model, which will provide an easy, quick, cheap, and reproducible alternative to cell-based MCC models; 3) We will apply an original technique called differential dynamic microscopy (DDM) to characterize the drug behaviour in the chip. DDM is perfectly adapted to measure particle diffusion in biological hydrogels under flowing conditions.
Our innovative screening platform will pave the way to design more efficient formulations to treat CRDs, with higher delivery rates, thereby improving the available treatments and lowering their costs. This project is in line with the United Nations’ aim “to reduce by 2030 by one-third premature mortality from non-communicable diseases [including CRDs] through prevention and treatment”.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.

Para utilizar esta función, debe iniciar sesión o registrarse

Coordinador

UNIVERSITE PARIS CITE
Aportación neta de la UEn
€ 195 914,88
Dirección
85 BD SAINT GERMAIN
75006 Paris
Francia

Ver en el mapa

Región
Ile-de-France Ile-de-France Paris
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos